Please Wait a Moment
X

Articles

15Jun

CTS Tampa Implementation date change for Ultrio Elite

15 Jun, 2020 | Return|

CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020.  The implementation date has been moved up to July 7th.  Contact your Customer Service Manager if you have any questions!

 

Related

Update on the Ortho Conversion

At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...

Read More >

Dr. Marion Lanteri Joins Creative Testing Solutions as Scientific Affairs VP

TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...

Read More >

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...

Read More >

The Reentry Changes Q & A document is now available

The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...

Read More >

Upcoming HCV Testing Algorithm Change

FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...

Read More >

CTS implements Ortho VIP Viral Marker Testing Platform

On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...

Read More >